Ankylose This! Living with Ankylosing Spondylitis

Friday, February 18, 2005

FDA: Celebrex still okay

The FDA says Celebrex can still be sold.

Food and Drug Administration advisory committee said Celebrex does pose an increased rink to patients taking it, but nonetheless allowed its makers to continue selling it because of the anti-inflammatory's effectiveness in relieving severe pain.

The FDA committee was expected to rule later in the day on two other painkillers in the COX-2 selective inhibitor class, Vioxx and Bextra.

It ruled on Celebrex first because it said the drug seems to pose a slightly lower risk of heart problems than the other two drugs.

Good news for Richard, even if as a Canadian he's not directly affected.

Update 4:23 PM: The article has been updated; Bextra and Vioxx are in, too.

Comments on this post

Post a Comment

Links to this post

Create a Link